Table 1 Study sample description
From: A blood DNA methylation biomarker for predicting short-term risk of cardiovascular events
Study name | Description | Country | N | Age means (min; max) | Female % | Training/Testing set |
|---|---|---|---|---|---|---|
EPIC Italy | Italian sub-sample of the European Investigation into Cancer and Nutrition study | Italy | 1803 | 53.3 (34.7; 74.9) | 62 | Training set for DNAm surrogates and DNAmCVDscore |
EXPOsOMICS CVD | Case–control study on CVD nested in the EPIC Italy cohort | Italy | 315 | 54.9 (35.2; 69.3) | 53 | Validation set for DNAm surrogates and DNAmCVDscore |
Understanding Society | The United Kingdom Household Panel Study (UKHLS) | UK | 1174 | 58.0 (28.0; 98.0) | 59 | Validation set for DNAm surrogates |
TILDA | The Irish Longitudinal Study on Ageing | Ireland | 490 | 62.1 (50.0; 80.0) | 50 | Validation set for DNAm surrogates |
GSE174818 | Case–control study on COVID-19 susceptibility and progression | USA | 127 | 61.8 (21.0; 90.0) | 40 | Validation set for DNAm surrogates |
NICOLA | The Northern Ireland Cohort for the Longitudinal Study of Ageing | UK | 1728 | 63.99 (40.0; 96.0) | 52 | Validation set for DNAmCVDscore |
HRS | The Health and Retirement Study | USA | 2146 | 68.76 (50.0;100.0) | 60 | Validation set for DNAmCVDscore |